NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
Clinical Trials
32 trialsNCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed
NCT03596281 2024-10-18
PEMBOV
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT03719326 2024-05-24
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT03639246 2023-02-13
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Aravive, Inc.
Phase 1 Completed
NCT00976131 2022-10-17
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
Columbia University
Phase 1 Completed
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT01445535 2021-11-03
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01902225 2020-06-09
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT02751918 2019-11-22
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Bayer
Phase 1 Completed
NCT00846612 2019-09-30
Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
NYU Langone Health
Phase 1 Completed
NCT01459380 2019-07-22
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01281514 2019-07-11
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT00761644 2019-04-11
Doxil, Bevacizumab and Temsirolimus Trial
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01489371 2019-03-12
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT01214668 2019-01-04
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00659178 2017-07-21
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
GlaxoSmithKline
Phase 1 Completed
NCT02262455 2017-02-13
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Phase 1 Completed
NCT02081495 2016-11-11
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT01815294 2015-12-04
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT01455532 2014-10-22
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Sanofi
Phase 1 Completed
NCT01702129 2014-09-09
Anti-EGFR Immunoliposomes in Solid Tumors
University Hospital, Basel, Switzerland
Phase 1 Completed
NCT00183742 2014-05-22
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
University of Southern California
Phase 1 Completed
NCT00316875 2013-11-08
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Northwestern University
Phase 1 Completed
NCT00290732 2013-10-31
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00003207 2013-04-12
Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers
Washington University School of Medicine
Phase 1 Completed
NCT00500422 2013-02-13
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00507962 2012-08-02
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
M.D. Anderson Cancer Center
Phase 1 Completed